"Anti-aging" is a marketing word. We use a clinical one.
"Anti-aging" promises something we can't deliver: time, in reverse. The honest version of what regenerative cellular medicine can offer is narrower and more useful. Modulating the systemic inflammation that accumulates with age, supporting the cells that maintain tissue homeostasis, and measurably improving the things people actually notice when they age: recovery time, joint comfort, sleep quality, energy.
We will not tell you we can extend your lifespan. We will not show you before-and-after photos of skin. We will not recommend a protocol because it is trending in longevity media.
What we will do is build a physician-prescribed protocol around your baseline biomarkers, your goals, and the published evidence — and tell you honestly which of those goals the evidence supports and which are still being investigated.
If your interest is cosmetic skin tightening or aesthetic facial work, that is not what this page describes. That is a different specialty and a different conversation. What follows is about systemic cellular medicine for adults who want their next decade to feel like their last, not the one after.
What changes at the cellular level.
The most widely cited framework in modern aging biology is the "hallmarks of aging" — a set of interconnected cellular changes that together account for the functional decline most adults experience after midlife.[1] Several of these hallmarks are particularly relevant to what regenerative cellular medicine attempts to influence.
Cellular senescence
Cells that have stopped dividing but refuse to clear, secreting a pro-inflammatory cocktail that drives "inflammaging" throughout surrounding tissue.[2]
Stem cell exhaustion
The body's resident progenitor populations lose regenerative capacity over decades, blunting tissue repair across bone marrow, muscle, and gut.
Mitochondrial dysfunction
Cumulative damage reduces cellular energy output and increases oxidative stress, dragging down everything that depends on ATP.
Chronic low-grade inflammation
The systemic state of "inflammaging" that correlates with cardiovascular disease, frailty, and cognitive decline.
Mesenchymal stem cells (MSCs) are biologically interesting in this context for one specific reason: their dominant mode of action is paracrine signaling — the secretion of immunomodulatory cytokines, growth factors, and exosomes that recalibrate the local and systemic inflammatory environment.[3] They are, in Caplan's framing, an "injury drugstore" rather than a tissue-replacement therapy. Whether that drugstore meaningfully alters age-related decline is a question the field is still actively answering.
The strongest published clinical signal so far is in aging frailty. A Phase II randomized, double-blind, placebo-controlled trial of allogeneic MSCs in patients with the frailty syndrome reported significant improvements in physical performance, inflammatory biomarkers (TNF-α), and quality-of-life measures at six months.[4] That matters because frailty is the closest thing aging medicine has to a measurable, treatable phenotype, and because it suggests the immunomodulatory effects of MSCs translate to functional outcomes in older adults.
The evidence base remains earlier-stage than for joint osteoarthritis. We will not overstate it.
What a vitality protocol looks like.
A vitality protocol at TrueCell is built around three things: a baseline biomarker panel, a calibrated cellular intervention, and a structured re-measurement at 3, 6, and 12 months. We treat the data as the protocol's accountability mechanism. If the numbers don't move, the protocol gets revised.
Baseline workup
- Inflammatory markers. High-sensitivity CRP, ESR, IL-6 where available.
- Metabolic panel. CMP, fasting insulin, HbA1c, lipid panel with apoB.
- Hormonal panel. Total and free testosterone (men), estradiol/FSH (women), DHEA-S, cortisol AM.
- Thyroid. TSH, free T3, free T4, reverse T3.
- CBC with differential. Baseline immune profile.
- Optional advanced markers where indicated: biological age estimates (epigenetic clocks where available), VO2 max, grip strength, body composition.
Patients who already have recent labs from their primary physician can submit them; we order what's missing.
The cellular intervention
Most vitality protocols are delivered intravenously to support systemic homing of cells to sites of inflammation throughout the body.
- UC-MSC IV infusion. 50M cells (anti-inflammatory dose) or 100M cells (high-dose). Wharton's jelly umbilical-cord-derived mesenchymal stem cells, prepared in our ISO-accredited laboratory, viability-verified before infusion.
- Muse cell IV. 1.5×10⁷ (standard) or 3.0×10⁷ (high-dose). A multilineage-differentiating subset within the MSC population with stress-tolerance and homing characteristics that distinguish them from conventional MSCs.[5]
- Systemic exosome infusion. The cell-free, extracellular-vesicle fraction. Useful as an adjunct or in patients for whom whole-cell infusion is not appropriate.
- Combination protocols. UC-MSC paired with intra-articular injections at the same visit for patients with concurrent joint OA.
Dose, route, and frequency are calibrated to your baseline. There is no "default" anti-aging protocol.
Re-measurement
Follow-up labs are repeated at 3, 6, and 12 months. The point is not to manufacture progress; it's to measure honestly whether the protocol is moving the markers we said it would. If a patient's hsCRP, IL-6, and functional measures are improving, we have data. If they aren't, that's also data, and we adjust.
Realistic outcomes.
First 72 hours
The IV infusion itself takes 60 to 90 minutes in a private suite. Most patients experience nothing remarkable during or immediately after. Some report mild fatigue or a transient low-grade flush in the first 24 hours, both of which resolve without intervention. Hydration and rest are the only requirements that evening.
Weeks 1 to 6
Subjective improvements, when they appear, tend to surface in this window. The most common patient reports are improved sleep quality, faster recovery from exercise, reduced morning joint stiffness, and a stable baseline of energy through the day. These are subjective — we do not treat them as clinical endpoints. The labs at month three are the more honest signal.
Months 3 to 6
Re-measurement of inflammatory markers (hsCRP, IL-6 where available) and functional measures. The Phase II frailty trial showed measurable improvements at six months in inflammatory biomarkers and physical performance after a single allogeneic MSC infusion in older adults.[4] Whether your numbers move similarly depends on your baseline, your underlying conditions, and your lifestyle in the months between.
Year 1 and re-treatment
Many patients in vitality protocols elect to repeat at 12 to 18 months, particularly when the baseline biomarkers indicate continued benefit and when lifestyle factors (sleep, training load, metabolic health) have been maintained. We do not push re-treatment on a calendar. The labs decide.
The point is not to manufacture progress. It's to measure honestly whether the protocol is moving the markers we said it would. If they aren't, that's also data, and we adjust.
What this protocol will not do
- Reverse a chronic disease that has not been independently treated — metabolic dysfunction, untreated sleep apnea, undiagnosed hormonal imbalance.
- Substitute for the foundations of healthy aging: sleep, resistance training, protein adequacy, lipid management, stress regulation.
- Provide cosmetic results. Skin tone, wrinkles, and aesthetic outcomes are not what the protocol targets.
- Guarantee an outcome. The evidence base supports a directional case, not a deterministic one.
Safety
Allogeneic MSC infusion has been studied across thousands of patients in cardiovascular, autoimmune, and aging-frailty contexts, with adverse events typically mild, transient, and self-limited.[4][6] The most common reactions are short-lived flushing, mild fatigue, or transient low-grade fever in the 24 to 48 hour window. Serious adverse events were rare across the cited datasets. We discuss the protocol-specific risk profile in writing during informed consent, before anything is scheduled.